Minaris

Philadelphia and Boston – September 24, 2026 -- Minaris, a global cell and gene therapy CDMO, has partnered with synthetic biology firm Asimov to integrate proprietary OXGENE viral vector technology into Asimov's AAV Edge producer cell lines, targeting higher manufacturing titers and improved product quality for adeno-associated virus (AAV) gene therapies.

Stable production systems aim to replace costly transient manufacturing

Most AAV programs currently rely on transient production, requiring multiple GMP plasmids to be transfected for every batch. This method drives up costs, limits scalability, and can produce inconsistent product quality. Stable production systems have historically been difficult to develop due to the complexity and interdependency of viral genetics involved.